Tuesday, 10 December 2019

14 February 2019

Pivotal achievement of 200 participants enrolled in the study!

We are pleased to celebrate the milestone achievement of the randomisation of 200 participants in the NeoVanc project. Congratulations to all the NeoVanc team!

A special mention needs to be made on the great effort of investigators, co-investigators and all researchers at recruiting sites involved in this key study on the use of Vancomycin in paediatrics. We look forward to continuing our work together towards reaching the project target of 300 evaluable participants and we wish the NeoVanc team the best of luck!

Funded by the European Commission’s FP7 programme, NeoVanc involves 12 European partners and is coordinated by Penta.

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Call: FP7-HEALTH-2013-INNOVATION-1
Privacy policy | Terms and conditions

E-mail: info@penta-id.org